XML 23 R11.htm IDEA: XBRL DOCUMENT v3.22.2
Financial Instruments
6 Months Ended
Jun. 30, 2022
Financial Instruments [Abstract]  
Financial Instruments NOTE 5. FINANCIAL INSTRUMENTS

Fair Value of Financial Instruments

Fair value is the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The fair value hierarchy established under GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows:

Level 1: quoted prices in active markets for identical assets or liabilities;

Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively.

We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability.

The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis as of June 30, 2022 and December 31, 2021 respectively:

June 30, 2022

December 31, 2021

(in thousands)

Level 1

Level 2

Level 3

Total

Level 1

Level 2

Level 3

Total

Assets

Cash and cash equivalents

102,612 

207,833 

310,445 

327,315 

133,410 

460,725 

Investments:

Commercial paper

120,495 

120,495 

187,632 

187,632 

Corporate debt securities

46,810 

46,810 

8,968 

8,968 

U.S. government & agency securities

421,401 

421,401 

387,075 

387,075 

Total investments

588,706 

588,706 

583,675 

583,675 

Short-term restricted cash

300 

300 

500 

500 

Long-term restricted cash

2,922 

2,922 

4,592 

4,592 

Total assets measured at fair value

$

105,834 

$

796,539 

$

$

902,373 

$

332,407 

$

717,085 

$

$

1,049,492 

Liabilities

Contingent consideration

$

$

$

163,216 

$

163,216 

$

$

$

169,717 

$

169,717 

Total liabilities measured at fair value

$

$

$

163,216 

$

163,216 

$

$

$

169,717 

$

169,717 

We classify contingent consideration, which was incurred in connection with the acquisition of Omniome, within Level 3 as factors used to develop the estimate of fair value include unobservable inputs that are not supported by market activity and are significant to the fair value.

We estimate the fair value of the contingent consideration liability by discounting the probability-weighted outcomes to present value using an estimate of our borrowing rate and the risk-free rate. The potential outcomes of milestone achievement dates are within the period from December 31, 2022 to June 30, 2025. A decrease in the probability of an earlier scenario within this range would result in a decrease in the fair value of the liability. The discount rates used are the sum of the U.S. risk-free rate and the estimated subordinated credit spread for B- and B credit rating, which range from 10.0% to 10.2%. An increase in the discount rates used can also result in the decrease in the fair value of liability, which was the primary factor in the $6.5 million decrease in liability at June 30, 2022. Changes in our estimated subordinated credit spread can result in changes in the fair value of the contingent consideration liability, where a lower credit spread may result in an increased liability valuation.

Changes in the estimated fair value of the contingent consideration liability for the six months ended June 30, 2022 were as follows:

(in thousands)

Level 3

Beginning balance as of December 31, 2021

$

169,717

Change in estimated fair value

(6,501)

Ending balance as of June 30, 2022

$

163,216

Changes to the fair value are recorded as the Change in fair value of contingent consideration in the Condensed Consolidated Statement of Operations and Comprehensive Loss.

For the six months ended June 30, 2022, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis, and our valuation techniques did not change compared to the prior year.

The following tables summarize our cash, cash equivalents and investments as of June 30, 2022 and December 31, 2021:

As of June 30, 2022

Gross

Gross

Amortized

unrealized

unrealized

Fair

(in thousands)

Cost

gains

losses

Value

Cash and cash equivalents

310,508

8

(71)

310,445

Investments:

Commercial paper

120,899

(404)

120,495

Corporate debt securities

47,083

(273)

46,810

U.S. government & agency securities

426,118

70

(4,787)

421,401

Total investments

594,100

70

(5,464)

588,706

Total cash, cash equivalents and investments

$

904,608

$

78

$

(5,535)

$

899,151

Short-term restricted cash

$

300

$

$

$

300

Long-term restricted cash

$

2,922

$

$

$

2,922

As of December 31, 2021

Gross

Gross

Amortized

unrealized

unrealized

Fair

(in thousands)

Cost

gains

losses

Value

Cash and cash equivalents

460,731

(5)

460,725

Investments:

Commercial paper

187,705

(73)

187,632

Corporate debt securities

8,964

9

(5)

8,968

U.S. government & agency securities

388,088

1

(1,014)

387,075

Total investments

584,757

10

(1,092)

583,675

Total cash, cash equivalents and investments

$

1,045,488

$

10

$

(1,097)

$

1,044,400

Short-term restricted cash

$

500

$

$

$

500

Long-term restricted cash

$

4,592

$

$

$

4,592

The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of June 30, 2022:

(in thousands)

Fair Value

Due in one year or less

$

687,193

Due after one year through five years

109,346

Total investments

$

796,539

Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.